These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
343 related articles for article (PubMed ID: 23896942)
1. The efficacy and safety of mirabegron in treating OAB: a systematic review and meta-analysis of phase III trials. Cui Y; Zong H; Yang C; Yan H; Zhang Y Int Urol Nephrol; 2014 Jan; 46(1):275-84. PubMed ID: 23896942 [TBL] [Abstract][Full Text] [Related]
2. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony). Abrams P; Kelleher C; Staskin D; Rechberger T; Kay R; Martina R; Newgreen D; Paireddy A; van Maanen R; Ridder A Eur Urol; 2015 Mar; 67(3):577-88. PubMed ID: 24612659 [TBL] [Abstract][Full Text] [Related]
3. Results of a randomized, double-blind, parallel-group, placebo- and active-controlled, multicenter study of mirabegron, a β3-adrenoceptor agonist, in patients with overactive bladder in Asia. Kuo HC; Lee KS; Na Y; Sood R; Nakaji S; Kubota Y; Kuroishi K Neurourol Urodyn; 2015 Sep; 34(7):685-92. PubMed ID: 25130281 [TBL] [Abstract][Full Text] [Related]
4. The role of mirabegron in overactive bladder: a systematic review and meta-analysis. Wu T; Duan X; Cao CX; Peng CD; Bu SY; Wang KJ Urol Int; 2014; 93(3):326-37. PubMed ID: 25115445 [TBL] [Abstract][Full Text] [Related]
5. Efficacy, safety, and tolerability of mirabegron in patients aged ≥65yr with overactive bladder wet: a phase IV, double-blind, randomised, placebo-controlled study (PILLAR). Wagg A; Staskin D; Engel E; Herschorn S; Kristy RM; Schermer CR Eur Urol; 2020 Feb; 77(2):211-220. PubMed ID: 31733990 [TBL] [Abstract][Full Text] [Related]
6. Critical analysis of phase II and III randomised control trials (RCTs) evaluating efficacy and tolerability of a β₃-adrenoceptor agonist (Mirabegron) for overactive bladder (OAB). Rossanese M; Novara G; Challacombe B; Iannetti A; Dasgupta P; Ficarra V BJU Int; 2015 Jan; 115(1):32-40. PubMed ID: 24602031 [TBL] [Abstract][Full Text] [Related]
7. Safety and Efficacy of Mirabegron: Analysis of a Large Integrated Clinical Trial Database of Patients with Overactive Bladder Receiving Mirabegron, Antimuscarinics, or Placebo. Chapple CR; Cruz F; Cardozo L; Staskin D; Herschorn S; Choudhury N; Stoelzel M; Heesakkers J; Siddiqui E Eur Urol; 2020 Jan; 77(1):119-128. PubMed ID: 31635815 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and Tolerability of Mirabegron Compared with Antimuscarinic Monotherapy or Combination Therapies for Overactive Bladder: A Systematic Review and Network Meta-analysis. Kelleher C; Hakimi Z; Zur R; Siddiqui E; Maman K; Aballéa S; Nazir J; Chapple C Eur Urol; 2018 Sep; 74(3):324-333. PubMed ID: 29699858 [TBL] [Abstract][Full Text] [Related]
9. Comparative efficacy and safety of medical treatments for the management of overactive bladder: a systematic literature review and mixed treatment comparison. Maman K; Aballea S; Nazir J; Desroziers K; Neine ME; Siddiqui E; Odeyemi I; Hakimi Z Eur Urol; 2014 Apr; 65(4):755-65. PubMed ID: 24275310 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study). Herschorn S; Chapple CR; Abrams P; Arlandis S; Mitcheson D; Lee KS; Ridder A; Stoelzel M; Paireddy A; van Maanen R; Robinson D BJU Int; 2017 Oct; 120(4):562-575. PubMed ID: 28418102 [TBL] [Abstract][Full Text] [Related]
11. Mirabegron for the treatment of overactive bladder: a prespecified pooled efficacy analysis and pooled safety analysis of three randomised, double-blind, placebo-controlled, phase III studies. Nitti VW; Khullar V; van Kerrebroeck P; Herschorn S; Cambronero J; Angulo JC; Blauwet MB; Dorrepaal C; Siddiqui E; Martin NE Int J Clin Pract; 2013 Jul; 67(7):619-32. PubMed ID: 23692526 [TBL] [Abstract][Full Text] [Related]
12. A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the β₃ adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder. Herschorn S; Barkin J; Castro-Diaz D; Frankel JM; Espuna-Pons M; Gousse AE; Stölzel M; Martin N; Gunther A; Van Kerrebroeck P Urology; 2013 Aug; 82(2):313-20. PubMed ID: 23769122 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and tolerability of mirabegron, a β(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial. Khullar V; Amarenco G; Angulo JC; Cambronero J; Høye K; Milsom I; Radziszewski P; Rechberger T; Boerrigter P; Drogendijk T; Wooning M; Chapple C Eur Urol; 2013 Feb; 63(2):283-95. PubMed ID: 23182126 [TBL] [Abstract][Full Text] [Related]
14. The efficacy and tolerability of the β3-adrenoceptor agonist mirabegron for the treatment of symptoms of overactive bladder in older patients. Wagg A; Cardozo L; Nitti VW; Castro-Diaz D; Auerbach S; Blauwet MB; Siddiqui E Age Ageing; 2014 Sep; 43(5):666-75. PubMed ID: 24610862 [TBL] [Abstract][Full Text] [Related]
15. Meta-analysis of the efficacy and safety of mirabegron and solifenacin monotherapy for overactive bladder. Wang J; Zhou Z; Cui Y; Li Y; Yuan H; Gao Z; Zhu Z; Wu J Neurourol Urodyn; 2019 Jan; 38(1):22-30. PubMed ID: 30350884 [TBL] [Abstract][Full Text] [Related]
16. Safety and efficacy of mirabegron as 'add-on' therapy in patients with overactive bladder treated with solifenacin: a post-marketing, open-label study in Japan (MILAI study). Yamaguchi O; Kakizaki H; Homma Y; Igawa Y; Takeda M; Nishizawa O; Gotoh M; Yoshida M; Yokoyama O; Seki N; Okitsu A; Hamada T; Kobayashi A; Kuroishi K BJU Int; 2015 Oct; 116(4):612-22. PubMed ID: 25639296 [TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of an α Herschorn S; Tarcan T; Jiang YH; Chung E; Abdul Hadi F; Steup A; Sumarsono B Neurourol Urodyn; 2024 Mar; 43(3):604-619. PubMed ID: 38291827 [TBL] [Abstract][Full Text] [Related]
18. Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a β(3)-adrenoceptor agonist, in overactive bladder. Chapple CR; Kaplan SA; Mitcheson D; Klecka J; Cummings J; Drogendijk T; Dorrepaal C; Martin N Eur Urol; 2013 Feb; 63(2):296-305. PubMed ID: 23195283 [TBL] [Abstract][Full Text] [Related]
19. Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability. Chapple CR; Cardozo L; Nitti VW; Siddiqui E; Michel MC Neurourol Urodyn; 2014 Jan; 33(1):17-30. PubMed ID: 24127366 [TBL] [Abstract][Full Text] [Related]
20. Mirabegron is alternative to antimuscarinic agents for overactive bladder without higher risk in hypertension: a systematic review and meta-analysis. Chen HL; Chen TC; Chang HM; Juan YS; Huang WH; Pan HF; Chang YC; Wu CM; Wang YL; Lee HY World J Urol; 2018 Aug; 36(8):1285-1297. PubMed ID: 29556972 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]